Myasthenia gravis: open trials in Denmark

• NCT04951622

  A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  Trial Treatment · Phase 3 · Janssen Research & Development, LLC

  Aalborg University Hospital, Aalborg · Rigshospitalet, Copenhagen Oe

  Registry updated 2026-11-05

• NCT07323316

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  Trial Treatment · Ad scientiam

  Aarhus University Hospital, Aarhus · Rigshospitalet, Copenhagen

  Registry updated 2026-11-05

• NCT07647510

  A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

  Trial Treatment · Phase 3 · Dianthus Therapeutics

  Rigshospitalet, Copenhagen · Region Nordjylland, Gistrup

  Registry updated 2026-10-30

• 2025-525127-27-00

  A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

  Trial Treatment · Phase 1/2 · Aurinia Pharmaceuticals Inc.

  Region Hovedstaden, Copenhagen Oe

  Registry updated 2026-10-13

• 2024-515627-10-00

  A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

  Trial Treatment · Phase 1/2 · Bonsai Biotherapeutics AB

  Rigshospitalet, Copenhagen Oe

  Registry updated 2026-09-09

• NCT06414954

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

  Trial Treatment · Phase 2 · NMD Pharma A/S

  Aarhus University Hospital, Aarhus · Rigshospitalet University of Copenhagen, Copenhagen

  Registry updated 2026-08-21

• NCT07039916

  Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

  Trial Treatment · Phase 3 · Immunovant Sciences GmbH

  Rigshospitalet, Copenhagen Oe

  Registry updated 2026-07-30

• 2023-507539-40-00

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis

  Trial Treatment · Phase 2 · NMD Pharma A/S

  Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe

  Registry updated 2026-02-26

All Myasthenia gravis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error